Desvenlafaxine + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dysthymic Disorder
Conditions
Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
Trial Timeline
Feb 1, 2012 → Dec 1, 2016
NCT ID
NCT01537068About Desvenlafaxine + Placebo
Desvenlafaxine + Placebo is a approved stage product being developed by Pfizer for Dysthymic Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01537068. Target conditions include Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01537068 | Approved | Completed |
Competing Products
1 competing product in Dysthymic Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine (Cymbalta) | Eli Lilly | Approved | 85 |